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Abstract
BACKGROUND: Secretory carcinoma (SC) of the salivary gland, also known as mammary analog secretory 
carcinoma, is a rare tumor in the parotid gland. This kind of tumor is characterized by generally indolent clinical 
behavior and expression of a break in the ETV6 gene. 
CASE REPORT: We present a unique case of secretory carcinoma and show its favorable prognoses.
CONCLUSION: Secretory carcinoma of the salivary gland is a low-grade carcinoma with a favorable prognosis. It has 
low regional lymph node and distant metastasis potential. Due to the possibility of misdiagnosis, immunohistochemical 
studies and FISH are suggested. The most effective treatment is complete surgical excision with negative surgical 
margins.
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Introduction
Secretory carcinoma (SC), formerly known as 
mammary analog secretory carcinoma (MASC), was 
renamed by WHO in the Classification of Head and 
Neck Tumors in 2017 [1]. In the beginning, this kind 
of tumor was first noticed in the breast and was called 
juvenile breast carcinoma and secretory carcinoma 
of the breast [2]. In 2010, Skálová found it occurring 
in the salivary gland and then named it MASC in 
salivary glands [3]. Secretory carcinoma is a low-grade 
malignant tumor and usually occurs in salivary glands, 
especially in the parotid gland (68%) [4].
It can be confused with acinic cell carcinoma 
(AciCC) and distinguished by immunohistochemical 
studies and fluorescence in situ hybridization (FISH). 
Complete surgical excision of secretory carcinoma 
is the treatment of choice, while gene fusion data 
can give us a better understanding of target therapy 
treatment.
We report a case of secretory carcinoma 
of the left parotid gland diagnosed and treated in 
our department. Left superficial parotidectomy was 
performed and the FISH study revealed a break-apart 
of ETV6 gene. No local recurrence was observed 
on physical examination and ultrasound on follow-up 
for 2 years.
Case Report
A 37-year-old man presented with a history 
of a left parotid mass that was gradually increasing in 
size for 6 months since October, 2017. No tenderness 
or facial numbness was noticed. On examination, he 
presented a firm, fixed, and non-tender mass on the left 
parotid region of about 6 × 5 cm2. Ultrasound showed 
a cystic mass and the result of fine-needle aspiration 
cytology report presented atypical cellular change. 
Contrast-enhanced computed tomography (CT) was 
performed for pre-surgical operation planning. One 
4.1 cm cystic mass with irregular wall thickening at the 
left parotid gland was noticed (Figure 1).
On the basis of radiological and cytological 
findings, the left side superficial parotidectomy was 
C - Case Reports Case Report in Dentistry
192 https://www.id-press.eu/mjms/index
performed under facial nerve monitoring (Figure 2). 
Histopathology revealed secretory carcinoma 
composed of cuboid or columnar epithelial cells 
(Figure 3). Immunohistochemical studies were positive 
for S-100 and CK7 and negative for p63, CK5/6, and 
DOG-1. FISH study revealed a break-apart of ETV6 
gene (Figure 4).
Figure  2:  Photo  of  the  surgery  demonstrating  left  superficial 
parotidectomy with preservation of facial nerve
No local recurrence was observed on physical 
examination and ultrasound on follow-up for 2 years.
Figure 3: Histopathology revealed secretory carcinoma composed of 
cuboid or columnar epithelial cells
Figure 4: Fluorescence in situ hybridization study showed positive for 
ETV6 gene rearrangement with loss of 3’ signals (green)
Discussion
Secretory carcinoma of the salivary gland 
is a rare type of tumor with generally indolent clinical 
behavior [4]. Its incidence is <0.5% in parotid malignant 
neoplasms [5] and usually presents as an asymptomatic 
mass in the parotid gland with slight male predilection 
(1.5:1) and the age span for SC is wide (5–77 years) [4]. 
It has also been reported in the nasal cavity, vulva, 
lacrimal gland [6], eyelid [7], skin [8], thyroid [9], and 
lung [10]. Most patients with SC present with a slowly 
growing painless tumor.
The diagnostic plan for SC includes ultrasound 
and image study (head and neck CT/magnetic resonance 
imaging). Although fine-needle aspiration may be performed 
during ultrasound evaluation, the cytology diagnosis for SC 
is poor. According to Kai et al., only 2 of 109 cytologists 
identified SC [11]. Immunohistochemistry and FISH studies 
using pathologic specimen can yield a definite diagnosis. 
In immunohistochemistry, SC is positive for S100, 
mammaglobin, and CK7 and negative for p63, CK5/6, and 
DOG-1 stains in the literature (Table 1) [12]. By FISH, SC 
shows ETV6 gene rearrangements. The most well-known 
fusion partner gene is NTRK3 (more than 90%) [13]. When 
fusions happen, the ETV6 gene enrolls – transcriptional 
regulator gene and the other genes (ex: NTRK3, MET, 
and RET) enroll a membrane receptor kinase. The above 
finding can lead to well-designed-target therapy in the 
literature [14]: We may choose Trk inhibitors (e.g., entrectinib 
and larotrectinib) for patients with a NTRK3 fusion gene and 
c-Met inhibitors (e.g., cabozantinib) for patients with a MET 
fusion gene if systemic therapy is needed [15] (Table 2).
The treatment of choice for SC is complete 
surgical excision. Due to the low incidence of lymph 
node involvement, elective neck dissection is not 
suggested for every case. Neither radiotherapy nor 
Figure 1: Computed tomography scan of head and neck showing a 
4.1 cm cystic mass (arrow) with irregular wall thickening at the left 
parotid gland
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chemotherapy is needed after the operation due to its 
favorable prognosis [4].
Table 1: Comparison of findings between SC and AciCC
In our case, the immunohistochemical studies 
were positive for S-100 and CK7 and negative for p63, 
CK5/6, and DOG-1. FISH study with a break-apart of ETV6 
gene was noticed. The diagnosis of MASC was confirmed.
Table 2: The gene rearrangements of SC and the suggestive 
target therapy
Although MASC is considered a low-grade 
malignant tumor in most cases, recurrence and disease 
dissemination still happen sometimes. Long-term 
follow-up is suggested.
Conclusion
Secretory carcinoma of the salivary gland is 
a low-grade carcinoma with a favorable prognosis. It 
has low regional lymph node and distant metastasis 
potential. Due to the possibility of misdiagnosis, 
immunohistochemical studies and FISH are suggested. 
The most effective treatment is complete surgical 
excision with negative surgical margins. FISH is 
recommended for SC patients, not only to provide 
definite result but also to obtain information for further 
target therapy if needed.
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